Applying Dry Powder Coatings - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Applying Dry Powder Coatings
The authors experiment with a resonant acoustic mixer as a method for dry powder coating.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 94-102

Acknowledgments

Thanks is given to Professor Rajesh Davé (New Jersey Institute of Technology) for his review, suggestions, and support.

Matthew P. Mullarney*, Beth A. Langdon, and Mark A. Polizzi are scientists in the dosage form development group at Pfizer, Eastern Point Rd, Groton, CT 06340, USA, tel. 860.715.4139, fax 860.441.3972,
. Lauren E. Beach, PhD, is currently a scientist in the pharmaceutical development group at Aprecia Pharmaceuticals.

*To whom all correspondence should be addressed.

Submitted: May 3, 2011. Accepted: June 24, 2011.

References

1. M.P. Mullarney et al., Powder Technol. 212 (3), 397–402 (2011).

2. R. Pfeffer et al., Powder Technol. 117 (1–2), 40–67 (2001).

3. M. Ramlakhan et al., Powder Technol. 112 (1–2), 137–148 (2000).

4. J. Tomas and S. Kleinschmidt, Chem. Eng. Technol. 32 (10), 1470–1483 (2009).

5. J. Yang et al., Powder Technol. 158 (1–3), 21–33 (2005).

6. D.K. Balachandran et al., Powder Technol., (in review).

7. H.W. Howe et al., "Apparatus and method for resonant-vibratory mixing," US patent 7,188,993, Jan. 2004.

8. H.W. Howe et al., "Method for Resonant-Vibratory Mixing," US patent 7,866,878, Jan. 2007.

9. A.W. Jenike, Storage and flow of solids: Bulletin No 123 of the Utah Engineering Experiment Station (University of Utah, Salt Lake City, UT, Ed. 16, Vol. 53, 1964),

10. A.K. Muller et al., Eur. J. Pharm. Sci. 34 (4–5), 303–308 (2008).

11. Q. Zhou et al., Powder Technol. 207 (1–3), 414–421 (2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here